[The anti-arrhythmic efficacy of sodium valproate].
The antiarrhythmic efficacy of the anticonvulsant sodium valproate was studied in 22 patients with ventricular premature contraction in the immediate (10-15 days) and late (2-5 months) periods of therapy. The prolong antiarrhythmic effect of the drug was observed in 66% of the patients in whom it was beneficial in the first days of therapy. The results obtained provide strong evidence for the efficacy of sodium valproate in patients with ventricular premature contraction occurring in the presence of neurocirculatory dystonia.
D000293:Adolescent; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000209:etiology; D004341:Drug Evaluation; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications; D009449:Neurocirculatory Asthenia / Q000150:complications; D014635:Valproic Acid / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D014635:Valproic Acid
Antiaritmicheskaia éffektivnost' natriia val'proata.